olaparib + Durvalumab
Phase 2Withdrawn 1 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
TNBC - Triple-Negative Breast Cancer
Conditions
TNBC - Triple-Negative Breast Cancer, BRCA1 Mutation, BRCA2 Mutation
Trial Timeline
Feb 1, 2024 → Jul 18, 2030
NCT ID
NCT05209529About olaparib + Durvalumab
olaparib + Durvalumab is a phase 2 stage product being developed by AstraZeneca for TNBC - Triple-Negative Breast Cancer. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT05209529. Target conditions include TNBC - Triple-Negative Breast Cancer, BRCA1 Mutation, BRCA2 Mutation.
What happened to similar drugs?
0 of 2 similar drugs in TNBC - Triple-Negative Breast Cancer were approved
Approved (0) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05209529 | Phase 2 | Withdrawn |
| NCT03594396 | Phase 1/2 | Active |
Competing Products
14 competing products in TNBC - Triple-Negative Breast Cancer